Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 15

1.

Comparison of antipsychotic medication effects on reducing violence in people with schizophrenia.

Swanson JW, Swartz MS, Van Dorn RA, Volavka J, Monahan J, Stroup TS, McEvoy JP, Wagner HR, Elbogen EB, Lieberman JA; CATIE investigators..

Br J Psychiatry. 2008 Jul;193(1):37-43. doi: 10.1192/bjp.bp.107.042630.

PMID:
18700216
2.

An open, large, 6-month naturalistic study of outcome in schizophrenic outpatients, treated with olanzapine.

Krzystanek M, Krupka-Matuszczyk I.

Hum Psychopharmacol. 2011 Jan;26(1):81-5. doi: 10.1002/hup.1173. Epub 2011 Feb 9. Review.

PMID:
23055416
3.

Atypical antipsychotics for psychosis in adolescents.

Kumar A, Datta SS, Wright SD, Furtado VA, Russell PS.

Cochrane Database Syst Rev. 2013 Oct 15;(10):CD009582. doi: 10.1002/14651858.CD009582.pub2. Review.

PMID:
24129841
4.

Perphenazine versus low-potency first-generation antipsychotic drugs for schizophrenia.

Tardy M, Huhn M, Engel RR, Leucht S.

Cochrane Database Syst Rev. 2014 Oct 7;(10):CD009369. doi: 10.1002/14651858.CD009369.pub2. Review.

PMID:
25290157
5.

Quetiapine versus typical antipsychotic medications for schizophrenia.

Suttajit S, Srisurapanont M, Xia J, Suttajit S, Maneeton B, Maneeton N.

Cochrane Database Syst Rev. 2013 May 31;(5):CD007815. doi: 10.1002/14651858.CD007815.pub2. Review.

PMID:
23728667
6.

Antipsychotic switching for people with schizophrenia who have neuroleptic-induced weight or metabolic problems.

Mukundan A, Faulkner G, Cohn T, Remington G.

Cochrane Database Syst Rev. 2010 Dec 8;(12):CD006629. doi: 10.1002/14651858.CD006629.pub2. Review.

PMID:
21154372
7.

Control group bias in randomized atypical antipsychotic medication trials for schizophrenia.

Woods SW, Gueorguieva RV, Baker CB, Makuch RW.

Arch Gen Psychiatry. 2005 Sep;62(9):961-70. Review.

PMID:
16143728
8.

Depot perphenazine decanoate and enanthate for schizophrenia.

David A, Quraishi S, Rathbone J.

Cochrane Database Syst Rev. 2005 Jul 20;(3):CD001717. Review.

PMID:
16034865
9.

Quetiapine versus other atypical antipsychotics for schizophrenia.

Asmal L, Flegar SJ, Wang J, Rummel-Kluge C, Komossa K, Leucht S.

Cochrane Database Syst Rev. 2013 Nov 18;(11):CD006625. doi: 10.1002/14651858.CD006625.pub3. Review.

PMID:
24249315
10.

Impact of atypical antipsychotics on quality of life in patients with schizophrenia.

Awad AG, Voruganti LN.

CNS Drugs. 2004;18(13):877-93. Review.

PMID:
15521791
11.

Lithium for schizophrenia.

Leucht S, Helfer B, Dold M, Kissling W, McGrath JJ.

Cochrane Database Syst Rev. 2015 Oct 28;(10):CD003834. doi: 10.1002/14651858.CD003834.pub3. Review.

PMID:
26509923
12.

Quetiapine for schizophrenia.

Srisurapanont M, Maneeton B, Maneeton N.

Cochrane Database Syst Rev. 2004;(2):CD000967. Review.

PMID:
15106155
13.

Choice of maintenance medication for schizophrenia.

Davis JM, Chen N.

J Clin Psychiatry. 2003;64 Suppl 16:24-33. Review.

PMID:
14680416
14.

The stable patient with schizophrenia--from antipsychotic effectiveness to adherence.

Thomas P.

Eur Neuropsychopharmacol. 2007 Mar;17 Suppl 2:S115-22. Review.

PMID:
17336766
15.

Does compliance therapy improve use of antipsychotic medication?

Ilott R.

Br J Community Nurs. 2005 Nov;10(11):514-9. Review.

PMID:
16301926

Supplemental Content

Support Center